임상시험 서비스 시장 : 서비스 유형별, 상별, 딜리버리 모델별, 시험 디자인별, 치료 분야별, 모달리티별, 최종사용자별, 지역별 - 세계 예측(-2031년)

The clinical trial services market is projected to reach USD 97.41 billion by 2031 from USD 66.20 billion in 2026, at a CAGR of 8.0% during the forecast period of 2026 to 2031.

The expanding pipeline of cell & gene therapies (CGTs) and precision medicines is increasing demand for specialized outsourced Phase I-IV clinical trial services. These programs often involve complex protocols, biomarker- or genomic-based patient selection, small and geographically dispersed patient populations, specialized site requirements, stringent sample handling, customized clinical supply and logistics, and extended safety follow-up. Such requirements are encouraging sponsors to engage CROs and specialized providers with capabilities in site identification and management, patient recruitment, clinical monitoring, laboratory and biomarker testing, data management, pharmacovigilance, and clinical trial logistics.

By service type, the laboratory services segment accounted for the second-largest share of the clinical trial services market in 2025.

By service type, the clinical trial services market is segmented into laboratory services, site management and monitoring, site contracts and payments, patient recruitment and retention, medical writing, clinical trial supply & logistics services, safety and pharmacovigilance, clinical trial data management services, consulting, and other clinical trial services. In 2025, laboratory services accounted for the second-largest share of the market, following site management and monitoring. The significant share of laboratory services stems from the extensive need for analytical and bioanalytical testing during Phase I-IV clinical trials to measure drug concentrations, evaluate pharmacokinetics, assess biomarkers and immunogenicity, and generate reliable laboratory data for efficacy and safety assessments. Increasing development of biologics, oncology therapies, cell & gene therapies, and other complex modalities is further increasing demand for specialized assays, biomarker testing, and high-quality bioanalytical capabilities, encouraging sponsors to outsource these activities to CROs and specialized laboratories.

By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the clinical trial services market in 2025.

Based on end user/sponsor, the clinical trial services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Pharmaceutical & biopharmaceutical companies are further segmented into large and mid-size and small companies. In 2025, pharmaceutical & biopharmaceutical companies accounted for the largest market share. This segment's large share is driven by extensive Phase I-IV clinical development pipelines, substantial R&D expenditure, increasing protocol complexity, and growing reliance on CROs for global trial execution. Outsourcing enables these sponsors to access specialized therapeutic expertise, global site and patient networks, scalable clinical operations resources, and capabilities in site management and monitoring, laboratory testing, data management, pharmacovigilance, patient recruitment, and clinical trial logistics while improving operational flexibility and development efficiency.

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America held the largest share of the global clinical trial services market, supported by a well-established pharmaceutical and biopharmaceutical industry, high R&D expenditure, and substantial demand for outsourced Phase I-IV clinical trial services. The region also benefits from a dense network of clinical research sites, hospitals, academic medical centers, and specialized laboratories, providing strong infrastructure for large-scale and complex clinical studies. In addition, the rapid adoption of decentralized and hybrid trial models, digital patient-engagement tools, risk-based monitoring, and advanced clinical data technologies, particularly in the US, is further supporting demand for services such as site management and monitoring, patient recruitment and retention, data management, pharmacovigilance, laboratory testing, and clinical trial logistics. These factors continue to strengthen North America's position as the leading regional market for outsourced clinical trial services.

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Fortrea (US)
• ICON Plc (Ireland)
• Syneos Health (US)
• Laboratory Corporation of America Holdings (US)
• Medpace (US)
• Wuxi AppTec (China)
• Frontage Labs (US)
• Pharmaron (US)
• Tigermed (China)
• SGS Societe Generale de Surveillance SA. (Switzerland)
• Eurofins Scientific (Luxembourg)
• Linical (Japan)
• Parexel International Corporation (US)
• Worldwide Clinical Trials (US)
• Novotech (Australia)
• PSI (Switzerland)
• Allucent (US)
• Premier Research (US)
• Clario (US)
• KCR S.A. (US)
• Rho, Inc. (US)
• Advanced Clinical (US)

Research Coverage

This research report categorizes the clinical trial services market by service type, phase, therapeutic area, modality, delivery model, study design, end user/sponsor, and region.

The report provides detailed information on the key drivers, opportunities, and challenges influencing the growth of the clinical trial services market, including increasing pipeline and trial complexity, growing R&D investment, service flexibility offered by CROs, demand for faster drug-development timelines, evolving outsourcing models, regulatory modernization, AI and data analytics, decentralized and patient/site-centric trials, patient recruitment and retention challenges, and shortages of specialized clinical research talent. It also analyzes industry trends, technology developments, regulatory and sustainability considerations, customer landscape, pricing, ecosystem dynamics, and the competitive landscape. A detailed assessment of key market participants covers their service portfolios, strategies, market positioning, partnerships, agreements, and other strategic developments, including service launches, deals, collaborations, partnerships, and acquisitions associated with the clinical trial services market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall clinical trial services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will help stakeholders understand the market's pulse and provide information on key market drivers, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (growing pipeline complexity and increasing clinical-trial activity in specialty therapies, growing R&D investments and presence of a robust clinical pipeline, service flexibility offered by CROs, demand for faster drug-development timelines and productivity improvement, and the gradual shift from full-service CRO toward FSP/hybrid/strategic outsourcing models), opportunities (regulatory modernization and innovative trial designs, AI, automation and data analytics in clinical development, and patient/site-centric and decentralized clinical trials), and challenges (patient recruitment and retention and shortage of qualified clinical research talent and specialized expertise) influencing the growth of the clinical trial services market
• Service Development/Innovation: Detailed insights into newly introduced and evolving clinical trial services and technology-enabled solutions
• Market Development: Comprehensive information about lucrative markets-the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, service offerings, and competitive positioning of key clinical trial service providers, including Thermo Fisher Scientific Inc. (PPD, Inc.), IQVIA Inc., ICON plc, Laboratory Corporation of America Holdings, Syneos Health, WuXi AppTec, Eurofins Scientific, Parexel International Corporation, Fortrea Inc., Medpace, SGS, Frontage Labs, Pharmaron, Tigermed, and BioAgile, among others. The report analyzes key strategies, service launches, deals, acquisitions, partnerships, agreements, collaborations, expansions, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics in the clinical trial services market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONAL SCOPE
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 GLOBAL CLINICAL TRIAL SERVICES MARKET SNAPSHOT
• 3.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY, 2025
• 3.3 CLINICAL TRIAL SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing pipeline complexity and increasing clinical-trial activity in specialty and advanced therapies
    • 4.2.1.2 Resilient biopharma R&D investment and broad clinical-development pipeline
    • 4.2.1.3 Flexible and scalable service delivery offered by CROs
    • 4.2.1.4 Pressure to shorten development timelines and improve clinical R&D productivity
    • 4.2.1.5 Growing adoption of FSP, hybrid, and strategic portfolio-based outsourcing models
  • 4.2.2 OPPORTUNITIES
    • 4.2.2.1 Regulatory modernization and adoption of innovative trial designs
    • 4.2.2.2 AI, automation, and advanced data analytics across clinical development
    • 4.2.2.3 Patient- and site-centric, decentralized, and hybrid clinical-trial models
  • 4.2.3 CHALLENGES
    • 4.2.3.1 Patient recruitment, enrollment, and retention constraints
    • 4.2.3.2 Shortage of qualified clinical-research talent and specialized domain expertise
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 MARKET TRENDS
  • 5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN
  • 5.1.2 INCREASING FOCUS ON IN SILICO TRIALS
  • 5.1.3 FSP AND HYBRID OUTSOURCING ARE GAINING STRATEGIC IMPORTANCE VERSUS ONE-SIZE-FITS-ALL FULL-SERVICE OUTSOURCING
  • 5.1.4 SUSTAINABILITY AND ESG PRESSURES ARE SHAPING CLINICAL TRIALS
  • 5.1.5 SUPPLIER CONSOLIDATION AND STRATEGIC PARTNERSHIPS REDEFINE MARKET
• 5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025
  • 5.3.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025
  • 5.3.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 INVESTMENT/FUNDING ACTIVITY
• 5.7 KEY CONFERENCES & EVENTS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 BARGAINING POWER OF SUPPLIERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 IMPACT OF 2025 TRUMP TARIFF ON CLINICAL TRIAL SERVICES MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 KEY TARIFF RATES
  • 5.9.3 PRICE IMPACT ANALYSIS
  • 5.9.4 IMPACT ON COUNTRY/REGION
    • 5.9.4.1 North America
      • 5.9.4.1.1 US
    • 5.9.4.2 Europe
    • 5.9.4.3 Asia Pacific
  • 5.9.5 IMPACT ON END-USE INDUSTRIES
    • 5.9.5.1 Pharmaceutical & biotech companies
    • 5.9.5.2 Medical devices companies
    • 5.9.5.3 Academic institutes
• 5.10 MACROECONOMIC OUTLOOK
  • 5.10.1 INTRODUCTION
  • 5.10.2 GDP TRENDS AND FORECAST
  • 5.10.3 TRENDS IN GLOBAL CLINICAL TRIAL SERVICES MARKET

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE N IMPACT, INNOVATIONS AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 AI-integrated Clinical Trial Management System (CTMS) & Electronic Trial Master File (eTMF) platforms
    • 6.1.1.2 Randomization and Trial Supply Management (RTSM)
    • 6.1.1.3 Electronic Data Capture (EDC) System
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Digital Biomarkers, Wearables & Electronic Patient-Reported Outcome (EPRO) Tools
    • 6.1.2.2 Model-Informed Drug Development (MIDD)
    • 6.1.2.3 Data Management and Informatics Technologies
    • 6.1.2.4 Real-world evidence (RWE) & real-world data (RWD) platforms
  • 6.1.3 ADJACENT TECHNOLOGY
    • 6.1.3.1 Clinical trial simulation tools
• 6.2 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET
  • 6.2.1 INTRODUCTION
  • 6.2.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES
  • 6.2.3 KEY COMPANIES IMPLEMENTING AI
  • 6.2.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM
• 6.3 TECHNOLOGY/SERVICE ROADMAP
• 6.4 FUTURE APPLICATIONS

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK & CLINICAL TRIAL AUTHORIZATION
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 CUSTOMER LANDSCAPE
  • 8.3.1 BUDGET ALLOCATION TREND
  • 8.3.2 ADOPTION BARRIER & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE

• 9.1 INTRODUCTION
• 9.2 CLINICAL TRIAL MANAGEMENT & MONITORING
  • 9.2.1 ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH
• 9.3 LABORATORY SERVICES
  • 9.3.1 ANALYTICAL TESTING SERVICES
    • 9.3.1.1 Increasing demand for analytical testing for drug development to drive market
  • 9.3.2 BIOANALYTICAL TESTING SERVICES
    • 9.3.2.1 Rising focus on biologics in advanced therapies to drive market
• 9.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES
  • 9.4.1 GROWING RELIANCE ON DATA FOR CLINICAL EVALUATIONS BY REGULATORY BODIES TO SUPPORT MARKET GROWTH
  • 9.4.2 BIOSTATISTICS
    • 9.4.2.1 Integration of real-world data (RWD) into statistical analysis to support market growth
  • 9.4.3 OTHER DATA MANAGEMENT SERVICES
• 9.5 CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES
  • 9.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET
• 9.6 CONSULTING
  • 9.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET
• 9.7 PATIENT RECRUITMENT & RETENTION
  • 9.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH
• 9.8 MEDICAL WRITING
  • 9.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET
• 9.9 SAFETY & PHARMACOVIGILANCE
  • 9.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH
• 9.10 SITE CONTRACTS & PAYMENTS
  • 9.10.1 GROWING NEED FOR STREAMLINED SITE CONTRACTING AND PAYMENT MANAGEMENT TO SUPPORT MARKET GROWTH
• 9.11 OTHER SERVICE TYPES

10 CLINICAL TRIAL SERVICES MARKET, BY PHASE

• 10.1 INTRODUCTION
• 10.2 PHASE III
  • 10.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING
• 10.3 PHASE II
  • 10.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS
• 10.4 PHASE I
  • 10.4.1 DECLINING TRIALS TO POSE GROWTH CHALLENGE TO MARKET
• 10.5 PHASE IV
  • 10.5.1 SIGNIFICANCE OF PHASE IV TO SUPPORT MARKET GROWTH

11 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL

• 11.1 INTRODUCTION
• 11.2 FULL-SERVICE OUTSOURCING (FSO) MODEL
  • 11.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 11.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
  • 11.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
• 11.4 HYBRID MODEL
  • 11.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH

12 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN

• 12.1 INTRODUCTION
• 12.2 INTERVENTIONAL
  • 12.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET
• 12.3 OBSERVATIONAL
  • 12.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH

13 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA

• 13.1 INTRODUCTION
• 13.2 ONCOLOGY
  • 13.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET
  • 13.2.2 BREAST CANCER
    • 13.2.2.1 Increasing cases and high spending on treating breast cancer to support growth
  • 13.2.3 LUNG CANCER
    • 13.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth
  • 13.2.4 COLORECTAL CANCER
    • 13.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth
  • 13.2.5 PROSTATE CANCER
    • 13.2.5.1 Growing clinical pipeline to propel market
  • 13.2.6 OTHER CANCER
• 13.3 NEUROLOGY
  • 13.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET
• 13.4 RESPIRATORY DISORDERS
  • 13.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH
• 13.5 METABOLIC DISORDERS/ENDOCRINOLOGY
  • 13.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH
• 13.6 CARDIOVASCULAR SYSTEM DISORDERS
  • 13.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET
• 13.7 DERMATOLOGY
  • 13.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR DIFFERENT SKIN CONDITIONS TO SUPPORT MARKET GROWTH
• 13.8 GASTROINTESTINAL DISEASES
  • 13.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET
• 13.9 IMMUNOLOGICAL DISORDERS
  • 13.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH
• 13.10 INFECTIOUS DISEASES
  • 13.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET
• 13.11 PSYCHIATRY
  • 13.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH
• 13.12 OPHTHALMOLOGY
  • 13.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
• 13.13 HEMATOLOGY
  • 13.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
• 13.14 GENITOURINARY & WOMEN'S HEALTH
  • 13.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET
• 13.15 OTHER THERAPEUTIC AREAS

14 CLINICAL TRIAL SERVICES MARKET, BY MODALITY

• 14.1 INTRODUCTION
• 14.2 SMALL MOLECULES
  • 14.2.1 STRONG PIPELINE GROWTH AND GROWING INVESTMENTS TO SUPPORT GROWTH
• 14.3 BIOLOGICS
  • 14.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND REGULATORY SUPPORT TO PROPEL DEMAND
• 14.4 MONOCLONAL ANTIBODY
  • 14.4.1 SURGING DEMAND FOR TARGETED THERAPIES TO DRIVE MARKET
• 14.5 CELL & GENE THERAPY
  • 14.5.1 DEVELOPMENT COMPLEXITY AND REGULATORY MOMENTUM TO DRIVE CRO DEMAND
• 14.6 OTHER BIOLOGICS
• 14.7 BIOSIMILARS
  • 14.7.1 INCREASING DEMAND FOR COST-EFFECTIVE ALTERNATIVES TO SUPPORT BIOSIMILARS GROWTH, THUS AIDING OUTSOURCING
• 14.8 MEDICAL DEVICES & IVD
  • 14.8.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND

15 CLINICAL TRIAL SERVICES MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 15.2.1 INCREASE IN R&D EXPENDITURE OF PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 15.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 15.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs
  • 15.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 15.2.3.1 Demand driven by limited internal capabilities and rising trial complexity
• 15.3 MEDICAL DEVICE COMPANIES
  • 15.3.1 RISING REGULATORY EVIDENCE REQUIREMENTS AND EXPANSION OF INTEGRATED SERVICE PORTFOLIOS BY MEDTECH CROS TO DRIVE MARKET GROWTH
• 15.4 ACADEMIC INSTITUTES
  • 15.4.1 EXPANDING CRO-ACADEMIC PARTNERSHIPS AND SITE NETWORKS TO DRIVE MARKET

16 CLINICAL TRIAL SERVICES MARKET, BY REGION

• 16.1 INTRODUCTION
• 16.2 NORTH AMERICA
  • 16.2.1 US
    • 16.2.1.1 Presence of well-established CROs to drive market
  • 16.2.2 CANADA
    • 16.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market
• 16.3 EUROPE
  • 16.3.1 GERMANY
    • 16.3.1.1 Growing R&D spending and favorable government policies to propel market
  • 16.3.2 UK
    • 16.3.2.1 Rising collaborations and improved policies to support market
  • 16.3.3 FRANCE
    • 16.3.3.1 Government-led support for effective drug research to drive market
  • 16.3.4 ITALY
    • 16.3.4.1 Government-led focus on improving clinical trial regulations to drive market
  • 16.3.5 SPAIN
    • 16.3.5.1 Rising R&D expenditure to boost market growth
  • 16.3.6 REST OF EUROPE
• 16.4 ASIA PACIFIC
  • 16.4.1 CHINA
    • 16.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market
  • 16.4.2 INDIA
    • 16.4.2.1 Cost-efficient and innovation-driven approach to propel market
  • 16.4.3 JAPAN
    • 16.4.3.1 Slight decline in number of clinical trials to limit market
  • 16.4.4 AUSTRALIA
    • 16.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market
  • 16.4.5 SOUTH KOREA
    • 16.4.5.1 Favorable government initiatives for drug development to drive market
  • 16.4.6 REST OF ASIA PACIFIC
• 16.5 LATIN AMERICA
  • 16.5.1 BRAZIL
    • 16.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market
  • 16.5.2 MEXICO
    • 16.5.2.1 Increasing investments in pharma R&D to drive market
  • 16.5.3 REST OF LATIN AMERICA
• 16.6 MIDDLE EAST
  • 16.6.1 GCC COUNTRIES
    • 16.6.1.1 Saudi Arabia
      • 16.6.1.1.1 Increase in collaborations to drive market
    • 16.6.1.2 UAE
      • 16.6.1.2.1 Growing clinical research activities to drive market
    • 16.6.1.3 Rest of GCC Countries
  • 16.6.2 REST OF MIDDLE EAST
  • 16.6.3 AFRICA
    • 16.6.3.1 Expanding pharmaceutical industry to support market growth

17 COMPETITIVE LANDSCAPE

• 17.1 OVERVIEW
• 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2025
• 17.3 REVENUE ANALYSIS, 2023-2025
  • 17.3.1 CLINICAL TRIAL SERVICES MARKET
• 17.4 MARKET SHARE ANALYSIS, 2025
  • 17.4.1 CLINICAL TRIAL SERVICES MARKET
• 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 17.5.1 CLINICAL TRIAL SERVICES MARKET
  • 17.5.2 STARS
  • 17.5.3 EMERGING LEADERS
  • 17.5.4 PERVASIVE PLAYERS
  • 17.5.5 PARTICIPANTS
    • 17.5.5.1 Company footprint: Key players, 2025
      • 17.5.5.1.1 Company footprint
    • 17.5.5.2 Region footprint
    • 17.5.5.3 Service type footprint
    • 17.5.5.4 Phase footprint
• 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 17.6.1 CLINICAL TRIAL SERVICES MARKET: STARTUPS/SMES, 2025
  • 17.6.2 PROGRESSIVE COMPANIES
  • 17.6.3 RESPONSIVE COMPANIES
  • 17.6.4 DYNAMIC COMPANIES
  • 17.6.5 STARTING BLOCKS
    • 17.6.5.1 Competitive benchmarking
      • 17.6.5.1.1 Detailed list of key startups/SMES
      • 17.6.5.1.2 Competitive benchmarking of startups/SMEs
• 17.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 17.7.1 CLINICAL TRIAL SERVICES MARKET
• 17.8 BRAND/SERVICE COMPARISON
• 17.9 COMPETITIVE SCENARIO
  • 17.9.1 SERVICE LAUNCHES
  • 17.9.2 DEALS
  • 17.9.3 EXPANSIONS

18 COMPANY PROFILES

• 18.1 KEY PLAYERS
  • 18.1.1 IQVIA INC.
    • 18.1.1.1 Business overview
    • 18.1.1.2 Solutions/Services offered
    • 18.1.1.3 Recent developments
      • 18.1.1.3.1 Service/Solution launches
      • 18.1.1.3.2 Deals
    • 18.1.1.4 MnM view
      • 18.1.1.4.1 Right to win
      • 18.1.1.4.2 Strategic choices
      • 18.1.1.4.3 Weaknesses and competitive threats
  • 18.1.2 ICON PLC
    • 18.1.2.1 Business overview
    • 18.1.2.2 Services/Solutions offered
    • 18.1.2.3 Recent developments
      • 18.1.2.3.1 Service launches
      • 18.1.2.3.2 Deals
      • 18.1.2.3.3 Expansions
    • 18.1.2.4 MnM view
      • 18.1.2.4.1 Right to win
      • 18.1.2.4.2 Strategic choices
      • 18.1.2.4.3 Weaknesses and competitive threats
  • 18.1.3 THERMO FISHER SCIENTIFIC INC.
    • 18.1.3.1 Business overview
    • 18.1.3.2 Services/Solutions offered
    • 18.1.3.3 Recent developments
      • 18.1.3.3.1 Product/Service launches
      • 18.1.3.3.2 Deals
      • 18.1.3.3.3 Expansions
    • 18.1.3.4 MnM view
      • 18.1.3.4.1 Right to win
      • 18.1.3.4.2 Strategic choices
      • 18.1.3.4.3 Weaknesses and competitive threats
  • 18.1.4 FORTREA
    • 18.1.4.1 Business overview
    • 18.1.4.2 Services/Solutions offered
    • 18.1.4.3 Recent developments
      • 18.1.4.3.1 Service launches
      • 18.1.4.3.2 Deals
      • 18.1.4.3.3 Expansions
      • 18.1.4.3.4 Other developments
    • 18.1.4.4 MnM view
      • 18.1.4.4.1 Right to win
      • 18.1.4.4.2 Strategic choices
      • 18.1.4.4.3 Weaknesses and competitive threats
  • 18.1.5 SYNEOS HEALTH
    • 18.1.5.1 Business overview
    • 18.1.5.2 Services/Solutions offered
    • 18.1.5.3 Recent developments
      • 18.1.5.3.1 Service launches
      • 18.1.5.3.2 Deals
  • 18.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 18.1.6.1 Business overview
    • 18.1.6.2 Services/Solutions offered
    • 18.1.6.3 Recent developments
      • 18.1.6.3.1 Service/ Solution launches
      • 18.1.6.3.2 Deals
      • 18.1.6.3.3 Expansions
    • 18.1.6.4 MnM view
      • 18.1.6.4.1 Right to win
      • 18.1.6.4.2 Strategic choices
      • 18.1.6.4.3 Weaknesses and competitive threats
  • 18.1.7 MEDPACE
    • 18.1.7.1 Business overview
    • 18.1.7.2 Services/Solutions offered
  • 18.1.8 WUXI APPTEC
    • 18.1.8.1 Business overview
    • 18.1.8.2 Services/Solutions offered
    • 18.1.8.3 Recent developments
      • 18.1.8.3.1 Deals
      • 18.1.8.3.2 Expansions
    • 18.1.8.4 Other developments
  • 18.1.9 FRONTAGE LABS
    • 18.1.9.1 Business overview
    • 18.1.9.2 Services/Solutions offered
    • 18.1.9.3 Recent developments
      • 18.1.9.3.1 Deals
  • 18.1.10 PHARMARON
    • 18.1.10.1 Business overview
    • 18.1.10.2 Services/Solutions offered
  • 18.1.11 TIGERMED
    • 18.1.11.1 Business overview
    • 18.1.11.2 Services offered
    • 18.1.11.3 Recent developments
      • 18.1.11.3.1 Service approvals
      • 18.1.11.3.2 Deals
  • 18.1.12 SGS SA
    • 18.1.12.1 Business overview
    • 18.1.12.2 Services/Solutions offered
    • 18.1.12.3 Recent developments
      • 18.1.12.3.1 Deals
      • 18.1.12.3.2 Expansions
  • 18.1.13 EUROFINS SCIENTIFIC
    • 18.1.13.1 Business overview
    • 18.1.13.2 Services/Solutions offered
  • 18.1.14 LINICAL
    • 18.1.14.1 Business overview
    • 18.1.14.2 Services/Solutions offered
    • 18.1.14.3 Recent developments
    • 18.1.14.4 Expansions
  • 18.1.15 PAREXEL INTERNATIONAL CORPORATION
    • 18.1.15.1 Business overview
    • 18.1.15.2 Services/Solutions offered
    • 18.1.15.3 Recent developments
      • 18.1.15.3.1 Product & service launches
      • 18.1.15.3.2 Deals
      • 18.1.15.3.3 Expansions
  • 18.1.16 PSI CRO AG
    • 18.1.16.1 Business overview
    • 18.1.16.2 Services/Solutions offered
    • 18.1.16.3 Recent developments
      • 18.1.16.3.1 Service launches
      • 18.1.16.3.2 Deals
      • 18.1.16.3.3 Expansions
  • 18.1.17 NOVOTECH
    • 18.1.17.1 Business overview
    • 18.1.17.2 Services/Solutions offered
    • 18.1.17.3 Recent developments
      • 18.1.17.3.1 Deals
  • 18.1.18 BIOAGILE
    • 18.1.18.1 Business overview
    • 18.1.18.2 Services/Solutions offered
  • 18.1.19 ADVANCED CLINICAL
    • 18.1.19.1 Business overview
    • 18.1.19.2 Services/Solutions offered
    • 18.1.19.3 Recent developments
      • 18.1.19.3.1 Deals
  • 18.1.20 FIRMA CLINICAL RESEARCH
    • 18.1.20.1 Business overview
    • 18.1.20.2 Services/Solutions offered
• 18.2 OTHER PLAYERS
  • 18.2.1 WORLDWIDE CLINICAL TRIALS
  • 18.2.2 PROPHARMA
  • 18.2.3 ALLUCENT
  • 18.2.4 PREMIER RESEARCH
  • 18.2.5 CAIDYA
  • 18.2.6 ERGOMED GROUP
  • 18.2.7 CLARIO
  • 18.2.8 PRECISION MEDICINE GROUP, LLC.
  • 18.2.9 EPS HOLDINGS, INC.
  • 18.2.10 GUIRES INC. (PEPGRA)
  • 18.2.11 KCR S.A.

19 RESEARCH METHODOLOGY

• 19.1 RESEARCH APPROACH
  • 19.1.1 SECONDARY DATA
    • 19.1.1.1 Key sources of secondary data
    • 19.1.1.2 Key objectives of secondary research
  • 19.1.2 PRIMARY DATA
    • 19.1.2.1 Breakdown of primaries
    • 19.1.2.2 Key objectives of primary research
• 19.2 MARKET ESTIMATION METHODOLOGY
  • 19.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
  • 19.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH
  • 19.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
• 19.3 GROWTH RATE PROJECTIONS
• 19.4 DATA TRIANGULATION
• 19.5 RESEARCH ASSUMPTIONS
• 19.6 RESEARCH LIMITATIONS
• 19.7 RISK ANALYSIS

20 APPENDIX

• 20.1 DISCUSSION GUIDE
• 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 20.3 CUSTOMIZATION OPTIONS
• 20.4 RELATED REPORTS
• 20.5 AUTHOR DETAILS